At present, immunotherapy for patients with melanoma has immunocheckpoint inhibitors, including CTLA-4 inhibitors and PD-1/PD-L1 inhibitors, which is one of the main immunotherapies used to treat melanoma. The gene discussed is CTLA4; the disease is melanoma.